Cargando…

Risk‐benefit analysis of use of statins for primary prevention of cardiovascular disease in subjects without diabetes

Detalles Bibliográficos
Autor principal:	Chan, Juliana CN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wiley-Blackwell 2013
Materias:	Commentaries
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020226/ https://www.ncbi.nlm.nih.gov/pubmed/24843676 http://dx.doi.org/10.1111/jdi.12076

Ejemplares similares

Statins alone or polypill for primary prevention of cardiovascular diseases
por: Hasani-Ranjbar, Shirin, et al.
Publicado: (2016)

Statin discontinuation: counterbalancing the benefits with the potential risks
por: Paraskevas, Kosmas I., et al.
Publicado: (2011)

Aspirin for primary prevention of cardiovascular disease in diabetes
por: Xing, Ying, et al.
Publicado: (2019)

Statin for the Primary Prevention of Cardiovascular Disease in Patients with Diabetes Mellitus
por: Koo, Bo Kyung
Publicado: (2014)

Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians – A population with the highest risk of premature coronary artery disease & diabetes
por: Enas, Enas A., et al.
Publicado: (2013)

Population Impact & Efficiency of Benefit‐Targeted Versus Risk‐Targeted Statin Prescribing for Primary Prevention of Cardiovascular Disease
por: Pletcher, Mark J., et al.
Publicado: (2017)

Do statins benefit low-risk population for primary prevention of atherosclerotic cardiovascular disease: A retrospective cohort study
por: Ryou, In Sun, et al.
Publicado: (2022)

Statins for primary prevention of cardiovascular disease and the risk of acute kidney injury
por: Coste, Joël, et al.
Publicado: (2019)

The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
por: Brugts, J J, et al.
Publicado: (2009)

Statins for primary cardiovascular prevention in the elderly
por: Pedro-Botet, Juan, et al.
Publicado: (2015)

Use of Aspirin and Statin as primary prevention for cardiovascular diseases
por: Alkhail, Bahaa Aba, et al.
Publicado: (2016)

Global variation of risk thresholds for initiating statins for primary prevention of cardiovascular disease: a benefit-harm balance modelling study
por: Yebyo, Henock G., et al.
Publicado: (2020)

Pesticide Testing on Human Subjects: Weighing Benefits and Risks
por: Resnik, David B., et al.
Publicado: (2005)

Older adult preferences regarding benefits and harms of statin and aspirin therapy for cardiovascular primary prevention()
por: Wang, Frances M., et al.
Publicado: (2023)

Net benefit of statins for primary prevention of cardiovascular disease in people 75 years or older: a benefit–harm balance modeling study
por: Yebyo, Henock G., et al.
Publicado: (2019)

Statins for the primary prevention of cardiovascular disease: an overview of systematic reviews
por: Byrne, Paula, et al.
Publicado: (2019)

Moving from the stratification of primary and secondary prevention of cardiovascular risk in diabetes towards a continuum of risk: need for a new paradigm
por: Garcia-Moll, Xavier, et al.
Publicado: (2021)

Iranian general populations' and health care providers' preferences for benefits and harms of statin therapy for primary prevention of cardiovascular disease
por: Saadati, Hassan, et al.
Publicado: (2020)

Survival Benefits of Statins for Primary Prevention: A Cohort Study
por: Gitsels, Lisanne A., et al.
Publicado: (2016)

Benefits of statin therapy and compliance in high risk cardiovascular patients
por: Lardizabal, Joel A, et al.
Publicado: (2010)

Primary prevention with statins in cardiovascular diseases: A Saudi Arabian perspective
por: Mahmood, D., et al.
Publicado: (2015)

Systematic review of the predictors of statin adherence for the primary prevention of cardiovascular disease
por: Hope, Holly F., et al.
Publicado: (2019)

Role of Statin Therapy in Primary Prevention of Cardiovascular Disease in Elderly Patients
por: Strandberg, Timo E.
Publicado: (2019)

Patterns of statin adherence in primary cardiovascular disease prevention during the pandemic
por: Malo, Sara, et al.
Publicado: (2022)

Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease
por: Shehadeh, Naim, et al.
Publicado: (2018)

Should statin guidelines consider patient preferences? Eliciting preferences of benefit and harm outcomes of statins for primary prevention of cardiovascular disease in the sub-Saharan African and European contexts
por: Yebyo, Henock G., et al.
Publicado: (2018)

Cardiovascular disease prevention: Risk factor modification at the heart of the matter
por: Fawzy, Ameenathul M., et al.
Publicado: (2021)

Do statins have a role in preventing or treating sepsis?
por: Novack, Victor, et al.
Publicado: (2006)

Public health guidance on cardiovascular benefits and risks related to fish consumption
por: Stern, Alan H
Publicado: (2007)

Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?
por: Tanaka, Atsushi, et al.
Publicado: (2017)

Statins for primary prevention of cardiovascular events and mortality in old and very old adults with and without type 2 diabetes: retrospective cohort study
por: Ramos, Rafel, et al.
Publicado: (2018)

Variations in statin prescribing for primary cardiovascular disease prevention: cross-sectional analysis
por: Fleetcroft, Robert, et al.
Publicado: (2014)

Statins for primary cardiovascular disease prevention among people with HIV: emergent directions
por: Fitch, Kathleen V., et al.
Publicado: (2022)

Diabetic Kidney Disease: A Determinant of Cardiovascular Risk in Type 1 Diabetes
por: de Boer, Ian H., et al.
Publicado: (2018)

Economic evaluation of statins in high-risk patients treated for primary and secondary prevention of cardiovascular disease in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2012)

Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease
por: Kohli-Lynch, Ciaran N., et al.
Publicado: (2022)

Aspirin for the Primary Prevention of Cardiovascular Events: A systematic review and meta-analysis comparing patients with and without diabetes
por: Calvin, Andrew D., et al.
Publicado: (2009)

Statins: benefits and risks revisited
por: Balaz, Miroslav, et al.
Publicado: (2019)

The Benefits and Risks of New Therapies for Type 2 Diabetes
por: Asche, Car V., et al.
Publicado: (2008)

Compliance in Primary Prevention With Statins and Associations With Cardiovascular Risk and Death in a Low‐Risk Population With Type 2 Diabetes Mellitus
por: Malmborg, Morten, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_0udl1add6ju6ita3c7kqiiojto